Eldesine
Brand names,
Eldesine
Analogs
Eldesine
Brand Names Mixture
Eldesine
Chemical_Formula
C43H55N5O7
Eldesine
RX_link
http://www.rxlist.com/cgi/generic2/vinor_cp.htm
Eldesine
fda sheet
Eldesine
msds (material safety sheet)
Eldesine
Synthesis Reference
G. J. Cullinan, K. Gerzon, Ger. pat. 2,415,980 (1974 to Lilly)
Eldesine
Molecular Weight
753.926 g/mol
Eldesine
Melting Point
230-232 oC
Eldesine
H2O Solubility
No information avaliable
Eldesine
State
Solid
Eldesine
LogP
4.002
Eldesine
Dosage Forms
IM solution; Powder for solution
Eldesine
Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Eldesine
Pharmacology
Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.
Eldesine
Absorption
No information avaliable
Eldesine
side effects and Toxicity
No information avaliable
Eldesine
Patient Information
Patient Information:
The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause
loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black
stool, bruising or bleeding.
Patients should be informed that the major acute toxicities of Vindesine are related to bone
marrow toxicity, specifically granulocytopenia with increased susceptibility to infection.
They should be advised to report fever or chills immediately. Women of childbearing potential
should be advised to avoid becoming pregnant during treatment. Patients should be advised to
contact their physician if they experience increased shortness of breath, cough, or other new
pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.
Eldesine
Organisms Affected
Humans and other mammals